CL2018003391A1 - Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma. - Google Patents
Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma.Info
- Publication number
- CL2018003391A1 CL2018003391A1 CL2018003391A CL2018003391A CL2018003391A1 CL 2018003391 A1 CL2018003391 A1 CL 2018003391A1 CL 2018003391 A CL2018003391 A CL 2018003391A CL 2018003391 A CL2018003391 A CL 2018003391A CL 2018003391 A1 CL2018003391 A1 CL 2018003391A1
- Authority
- CL
- Chile
- Prior art keywords
- pro
- fork
- refers
- pharmaceutical
- activity
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 230000002849 elastaseinhibitory effect Effects 0.000 title 1
- 239000000816 peptidomimetic Substances 0.000 title 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 239000008249 pharmaceutical aerosol Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 108010028275 Leukocyte Elastase Proteins 0.000 abstract 1
- 102000016799 Leukocyte elastase Human genes 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A AEROSOLES FARMACÉUTICOS QUE COMPRENDEN UNA ß-HORQUILLA PEPTIDOMIMÉTICA DE FÓRMULA CICLO(-OCTG-GLU-THR-ALA-SER-ILE-PRO-PRO-GLN-LYS-TYR-DPRO-PRO-), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, QUE TIENE ACTIVIDAD INHIBIDORA CONTRA ELASTASA DE NEUTRÓFILO HUMANA. ADEMÁS, SE REFIERE A COMPOSICIONES FARMACÉUTICAS SÓLIDAS O LÍQUIDAS Y KITS PARA PREPARAR Y ADMINISTRAR TALES AEROSOLES. LA INVENCIÓN SE PUEDE UTILIZAR PARA LA PREVENCIÓN, MANEJO O TRATAMIENTO DE ENFERMEDADES PULMONARES, TAL COMO LA DEFICIENCIA DE ANTITRIPSINA ALFA-1 (AATD), FIBROSIS QUÍSTICA (CF), BRONQUIACTASIA FIBROSA NO QUÍSTICA (NCFB) O ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA (COPD), O INFECCIONES, O ENFERMEDADES O AFECCIONES DE LOS PULMONES, QUE SON MEDIADAS O QUE RESULTAN DE LA ACTIVIDAD DE LA ELASTASA DE NEUTRÓFILO HUMANA. POR LO TANTO, LA INVENCIÓN SE REFIERE ADEMÁS A UNA COMPOSICIÓN FARMACÉUTICA O UN AEROSOL FARMACÉUTICO QUE COMPRENDE EL COMPUESTO ACTIVO CICLO(-OCTG-GLU-THR-ALA-SER-ILE-PRO-PRO-GLN-LYS-TYR-DPRO-PRO-), O CUALQUIER SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, PARA USO EN UN MÉTODO PARA LA PREVENCIÓN, MANEJO O TRATAMIENTO DE ENFERMEDADES O AFECCIONES DE LOS PULMONES QUE SON MEDIADAS O QUE RESULTAN DE LA ACTIVIDAD DE LA ELASTASA DE NEUTRÓFILO EN UN SUJETO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020210 | 2016-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003391A1 true CL2018003391A1 (es) | 2019-05-03 |
Family
ID=56108445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003391A CL2018003391A1 (es) | 2016-05-31 | 2018-11-28 | Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma. |
| CL2018003390A CL2018003390A1 (es) | 2016-05-31 | 2018-11-28 | Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003390A CL2018003390A1 (es) | 2016-05-31 | 2018-11-28 | Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11235024B2 (es) |
| EP (2) | EP3463281B1 (es) |
| JP (4) | JP7544466B2 (es) |
| KR (2) | KR102480800B1 (es) |
| CN (3) | CN116159024A (es) |
| AU (2) | AU2017273508B2 (es) |
| BR (2) | BR112018074532B1 (es) |
| CA (2) | CA3024521C (es) |
| CL (2) | CL2018003391A1 (es) |
| DK (2) | DK3463281T3 (es) |
| EA (2) | EA039603B1 (es) |
| ES (2) | ES2927948T3 (es) |
| HR (2) | HRP20221194T1 (es) |
| HU (2) | HUE060393T2 (es) |
| IL (2) | IL263112B2 (es) |
| LT (2) | LT3463281T (es) |
| MA (2) | MA45167A (es) |
| MX (2) | MX393629B (es) |
| PH (2) | PH12018502521A1 (es) |
| PL (2) | PL3463281T3 (es) |
| PT (2) | PT3463281T (es) |
| RS (2) | RS63639B1 (es) |
| SG (3) | SG10202113280XA (es) |
| SM (2) | SMT202200405T1 (es) |
| UA (2) | UA125899C2 (es) |
| WO (2) | WO2017207117A1 (es) |
| ZA (2) | ZA201807772B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202113280XA (en) * | 2016-05-31 | 2021-12-30 | Polyphor Ag | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
| EP4017497A4 (en) * | 2019-08-23 | 2024-01-10 | pH Pharma Co., Ltd. | USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASES |
| BR112022014861A2 (pt) * | 2020-01-30 | 2022-09-20 | Vertex Pharma | Métodos de tratamento para deficiência de alfa-1 antittripsina |
| KR20230123950A (ko) * | 2020-11-23 | 2023-08-24 | 스펙시스 아게 | 베타-헤어핀 펩티도미메틱의 조성물 및 이의 에어로졸 투여 형태 |
| CN116421704A (zh) * | 2023-02-20 | 2023-07-14 | 成都佩德生物医药有限公司 | 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998019694A1 (en) * | 1996-11-01 | 1998-05-14 | Xoma Corporation | Therapeutic uses of bpi protein products in cystic fibrosis patients |
| AU2006206272A1 (en) | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
| US8658604B2 (en) * | 2005-02-17 | 2014-02-25 | Polyphor Ltd | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity |
| EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| US7973005B2 (en) * | 2006-02-09 | 2011-07-05 | Kamada Ltd. | Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases |
| HUE037773T2 (hu) * | 2006-02-10 | 2018-09-28 | Pari Pharma Gmbh | Porlasztott antibiotikumok inhalációs terápiához |
| WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
| EP1927373B1 (en) * | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
| ES2532667T3 (es) * | 2011-09-12 | 2015-03-30 | Meiji Seika Pharma Co., Ltd. | Composiciones acuosas que contienen arbekacina |
| WO2015096672A1 (zh) | 2013-12-23 | 2015-07-02 | 石家庄铁道大学 | 测试装置 |
| JP6431486B2 (ja) | 2013-12-26 | 2018-11-28 | 株式会社カネカ | 太陽電池のｉ‐ｖ測定方法、太陽電池のｉ‐ｖ測定装置、太陽電池の製造方法、太陽電池モジュールの製造方法、および太陽電池モジュール |
| MX389053B (es) * | 2013-12-27 | 2025-03-20 | Polyphor Ag | Peptidomimeticos de horquilla beta como inhibidores de elastasa selectivos. |
| BR112016015018B1 (pt) * | 2013-12-27 | 2022-10-04 | Polyphor Ag | Composto peptídico ciclizado na cadeia principal, composição farmacêutica, uso de um composto, método para tratar uma infecção ou uma doença ou distúrbio, e, processo para a fabricação de um composto |
| SG10202113280XA (en) * | 2016-05-31 | 2021-12-30 | Polyphor Ag | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
-
2017
- 2017-05-31 SG SG10202113280XA patent/SG10202113280XA/en unknown
- 2017-05-31 CN CN202211636345.7A patent/CN116159024A/zh active Pending
- 2017-05-31 EP EP17733738.3A patent/EP3463281B1/en active Active
- 2017-05-31 KR KR1020187036054A patent/KR102480800B1/ko active Active
- 2017-05-31 AU AU2017273508A patent/AU2017273508B2/en not_active Ceased
- 2017-05-31 PT PT177337383T patent/PT3463281T/pt unknown
- 2017-05-31 LT LTEPPCT/EP2017/025157T patent/LT3463281T/lt unknown
- 2017-05-31 US US16/305,714 patent/US11235024B2/en active Active
- 2017-05-31 MA MA045167A patent/MA45167A/fr unknown
- 2017-05-31 JP JP2018562549A patent/JP7544466B2/ja active Active
- 2017-05-31 MA MA045168A patent/MA45168A/fr unknown
- 2017-05-31 US US16/305,518 patent/US11235023B2/en active Active
- 2017-05-31 SG SG11201810137UA patent/SG11201810137UA/en unknown
- 2017-05-31 HR HRP20221194TT patent/HRP20221194T1/hr unknown
- 2017-05-31 WO PCT/EP2017/025156 patent/WO2017207117A1/en not_active Ceased
- 2017-05-31 RS RS20220922A patent/RS63639B1/sr unknown
- 2017-05-31 ES ES17733737T patent/ES2927948T3/es active Active
- 2017-05-31 IL IL263112A patent/IL263112B2/en unknown
- 2017-05-31 AU AU2017273507A patent/AU2017273507B2/en not_active Ceased
- 2017-05-31 ES ES17733738T patent/ES2928050T3/es active Active
- 2017-05-31 PL PL17733738.3T patent/PL3463281T3/pl unknown
- 2017-05-31 CN CN201780033188.1A patent/CN109310613A/zh active Pending
- 2017-05-31 JP JP2018562561A patent/JP7286319B6/ja active Active
- 2017-05-31 MX MX2018014752A patent/MX393629B/es unknown
- 2017-05-31 BR BR112018074532-4A patent/BR112018074532B1/pt not_active IP Right Cessation
- 2017-05-31 LT LTEPPCT/EP2017/025156T patent/LT3463280T/lt unknown
- 2017-05-31 SM SM20220405T patent/SMT202200405T1/it unknown
- 2017-05-31 DK DK17733738.3T patent/DK3463281T3/da active
- 2017-05-31 RS RS20220923A patent/RS63622B1/sr unknown
- 2017-05-31 EA EA201892818A patent/EA039603B1/ru unknown
- 2017-05-31 HU HUE17733738A patent/HUE060393T2/hu unknown
- 2017-05-31 UA UAA201812929A patent/UA125899C2/uk unknown
- 2017-05-31 IL IL263114A patent/IL263114B2/en unknown
- 2017-05-31 MX MX2018014425A patent/MX2018014425A/es unknown
- 2017-05-31 CA CA3024521A patent/CA3024521C/en active Active
- 2017-05-31 PL PL17733737.5T patent/PL3463280T3/pl unknown
- 2017-05-31 WO PCT/EP2017/025157 patent/WO2017207118A1/en not_active Ceased
- 2017-05-31 HU HUE17733737A patent/HUE060119T2/hu unknown
- 2017-05-31 UA UAA201812930A patent/UA125900C2/uk unknown
- 2017-05-31 SM SM20220404T patent/SMT202200404T1/it unknown
- 2017-05-31 BR BR112018074551-0A patent/BR112018074551B1/pt not_active IP Right Cessation
- 2017-05-31 CA CA3024522A patent/CA3024522C/en active Active
- 2017-05-31 KR KR1020187036055A patent/KR102511284B1/ko active Active
- 2017-05-31 PT PT177337375T patent/PT3463280T/pt unknown
- 2017-05-31 SG SG11201810138XA patent/SG11201810138XA/en unknown
- 2017-05-31 HR HRP20221185TT patent/HRP20221185T1/hr unknown
- 2017-05-31 EA EA201892819A patent/EA201892819A1/ru unknown
- 2017-05-31 CN CN201780033187.7A patent/CN109195580A/zh active Pending
- 2017-05-31 DK DK17733737.5T patent/DK3463280T3/da active
- 2017-05-31 EP EP17733737.5A patent/EP3463280B1/en active Active
-
2018
- 2018-11-19 ZA ZA2018/07772A patent/ZA201807772B/en unknown
- 2018-11-19 ZA ZA2018/07773A patent/ZA201807773B/en unknown
- 2018-11-28 CL CL2018003391A patent/CL2018003391A1/es unknown
- 2018-11-28 CL CL2018003390A patent/CL2018003390A1/es unknown
- 2018-11-29 PH PH12018502521A patent/PH12018502521A1/en unknown
- 2018-11-29 PH PH12018502522A patent/PH12018502522A1/en unknown
-
2021
- 2021-10-06 US US17/495,137 patent/US11844823B2/en active Active
-
2022
- 2022-01-04 JP JP2022000083A patent/JP2022078013A/ja active Pending
- 2022-10-20 JP JP2022168582A patent/JP2023017793A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003390A1 (es) | Beta-horquilla peptidomimética con actividad inhibidora de elastasa y formas de dosificación en aerosol de la misma. | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| MX2017002028A (es) | Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7). | |
| UY35963A (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| ECSP13013035A (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida | |
| CY1119645T1 (el) | Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης | |
| MX2018005708A (es) | Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7. | |
| CO6690744A2 (es) | Formulación de polvo seco que comprende un inhibidor de fosfodiesterasa | |
| NZ708593A (en) | Novel pyrazole derivative | |
| CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| HK1247822A1 (zh) | 用於活性剂口服给药的制剂 | |
| CL2014000311A1 (es) | Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio. | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| DOP2016000253A (es) | Nuevos compuestos | |
| UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| CO2020013427A2 (es) | Formulaciones de ciclosporina para uso en el tratamiento del síndrome de bronquiolitis obliterante (bos) | |
| CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. | |
| CL2014003361A1 (es) | Profarmaco de ácido fosforamidico del compuesto 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida; composicion farmaceutica y uso en el tratamiento o la prevencion de la arritmia. | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CL2013002325A1 (es) | Compuestos derivados de 4-amino-2-butenamidas, inhibidores de catepsina c; composicion farmaceutica que los comprende; procedimiento de preparacion de la composicion farmaceutica; uso del compuesto en el tratamiento de enfermedad pulmonar obstructiva cronica. |